Segments

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

SEGMENTS

SEGMENTS

We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical and genomics laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:

	For the three months ended September 30,				For the nine months ended September 30,
(In thousands)	2022		2021		2022		2021
Revenue from services:
Pharmaceutical	$	—	$	—	$	—	$	—
Diagnostics	142,856		340,163		616,259		1,244,312
Corporate	—		—		—		—
	$	142,856	$	340,163	$	616,259	$	1,244,312
Revenue from products:
Pharmaceutical	$	32,388	$	36,882	$	104,938	$	106,490
Diagnostics	—		—		—		—
Corporate	—		—		—		—
	$	32,388	$	36,882	$	104,938	$	106,490
Revenue from transfer of intellectual property and other:
Pharmaceutical	$	4,500	$	8,768	$	97,659	$	22,585
Diagnostics	—		—		—		—
Corporate	—		—		—		—
	$	4,500	$	8,768	$	97,659	$	22,585
Operating income (loss):
Pharmaceutical	$	(28,298)	$	28,625	$	9,020	$	(4,251)
Diagnostics	(49,454)		19,658		(150,537)		116,670
Corporate	(10,068)		(10,457)		(29,467)		(30,585)
	$	(87,820)	$	37,826	$	(170,984)	$	81,834
Depreciation and amortization:
Pharmaceutical	$	17,840	$	6,080	$	50,882	$	20,500
Diagnostics	10,155		12,883		31,313		39,025
Corporate	—		—		—		—
	$	27,995	$	18,963	$	82,195	$	59,525
Loss from investment in investees:
Pharmaceutical	$	(43)	$	(53)	$	(359)	$	(163)
Diagnostics	—		—		—		—
Corporate	—		—		—		—
	$	(43)	$	(53)	$	(359)	$	(163)
Revenues:
United States	$	149,841	$	354,586	$	634,754	$	1,269,749
Ireland	6,680		5,445		104,318		24,663
Chile	14,347		16,486		46,490		49,294
Spain	4,564		5,721		17,370		17,077
Israel	251		307		3,663		3,543
Mexico	3,886		3,162		11,691		8,619
Other	174		106		570		442
	$	179,744	$	385,813	$	818,856	$	1,373,387

(In thousands)	September 30, 2022		December 31, 2021
Assets:
Pharmaceutical	$	1,297,347	$	1,114,460
Diagnostics	697,118		1,238,583
Corporate	230,320		46,672
	$	2,224,785	$	2,399,715
Goodwill:
Pharmaceutical	$	290,474	$	237,576
Diagnostics	283,025		283,025
	$	573,499	$	520,601

No customer represented more than 10% of our total consolidated revenue during the nine months ended September 30, 2022 and 2021. As of September 30, 2022 and December 31, 2021, no customer represented more than 10% of our accounts receivable balance.